CN113710230A - 用于调节补体活性的组合物和方法 - Google Patents

用于调节补体活性的组合物和方法 Download PDF

Info

Publication number
CN113710230A
CN113710230A CN202080030772.3A CN202080030772A CN113710230A CN 113710230 A CN113710230 A CN 113710230A CN 202080030772 A CN202080030772 A CN 202080030772A CN 113710230 A CN113710230 A CN 113710230A
Authority
CN
China
Prior art keywords
release formulation
polypeptide
extended release
inhibitor
zirukopril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030772.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·里德
E·塔卡贝里
王宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Inc
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of CN113710230A publication Critical patent/CN113710230A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080030772.3A 2019-04-24 2020-04-24 用于调节补体活性的组合物和方法 Pending CN113710230A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962837978P 2019-04-24 2019-04-24
US62/837,978 2019-04-24
US201962947183P 2019-12-12 2019-12-12
US201962947188P 2019-12-12 2019-12-12
US62/947,188 2019-12-12
US62/947,183 2019-12-12
PCT/US2020/029733 WO2020219822A1 (en) 2019-04-24 2020-04-24 Compositions and methods for modulating complement activity

Publications (1)

Publication Number Publication Date
CN113710230A true CN113710230A (zh) 2021-11-26

Family

ID=70977557

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030772.3A Pending CN113710230A (zh) 2019-04-24 2020-04-24 用于调节补体活性的组合物和方法

Country Status (13)

Country Link
US (1) US20220211799A1 (enExample)
EP (1) EP3958842A1 (enExample)
JP (2) JP7726791B2 (enExample)
KR (1) KR20220004039A (enExample)
CN (1) CN113710230A (enExample)
AU (1) AU2020261059A1 (enExample)
BR (1) BR112021017820A2 (enExample)
CA (1) CA3137895A1 (enExample)
IL (1) IL287079A (enExample)
MX (1) MX2021013010A (enExample)
SG (1) SG11202109837SA (enExample)
TW (1) TW202106290A (enExample)
WO (1) WO2020219822A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055931T2 (hu) 2014-06-12 2022-01-28 Ra Pharmaceuticals Inc A komplementaktivitás modulálása
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
AU2016370210A1 (en) 2015-12-16 2018-06-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂
CA3115828A1 (en) * 2018-10-22 2020-04-30 Ra Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1524516A (zh) * 2003-09-18 2004-09-01 中国人民解放军第二军医大学 胰高血糖素样肽－1缓释微球制剂及其用途
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
CN103347895A (zh) * 2010-10-01 2013-10-09 阿雷克森制药公司 与人补体成分c5结合的多肽
US20160324798A1 (en) * 2013-12-31 2016-11-10 Heron Therapeutics, Inc. Polymer-based compositions for extended release of proteins
CN106456701A (zh) * 2014-06-12 2017-02-22 Ra制药公司 补体活性的调节
US20180282425A1 (en) * 2017-04-03 2018-10-04 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
CN108697759A (zh) * 2015-12-16 2018-10-23 Ra制药公司 补体活性的调节剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241139A (zh) * 1996-12-20 2000-01-12 武田药品工业株式会社 生产缓释制剂的方法
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US8329169B2 (en) 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CA2623561C (en) 2005-09-27 2015-04-28 Efrat Biopolymers Ltd. Gelling hydrophobic injectable polymer compositions
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
JP2009521213A (ja) * 2005-12-24 2009-06-04 ティーガスク デイリー プロダクツ リサーチ センター トランス−１０，シス−１２オクタデカジエン酸を製造する方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
PT2698166E (pt) 2006-10-10 2016-01-27 Regenesance B V Inibição do complemento para regeneração nervosa aprimorada
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
CA2680833A1 (en) 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
KR101572700B1 (ko) 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
US20110142837A1 (en) 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
JP5473925B2 (ja) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
CA2977981C (en) 2015-02-27 2023-03-21 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1524516A (zh) * 2003-09-18 2004-09-01 中国人民解放军第二军医大学 胰高血糖素样肽－1缓释微球制剂及其用途
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
CN103347895A (zh) * 2010-10-01 2013-10-09 阿雷克森制药公司 与人补体成分c5结合的多肽
US20160324798A1 (en) * 2013-12-31 2016-11-10 Heron Therapeutics, Inc. Polymer-based compositions for extended release of proteins
CN106456701A (zh) * 2014-06-12 2017-02-22 Ra制药公司 补体活性的调节
CN108697759A (zh) * 2015-12-16 2018-10-23 Ra制药公司 补体活性的调节剂
US20180369322A1 (en) * 2015-12-16 2018-12-27 Ra Pharmaceuticals, Inc. Modulators of complement activity
US20180282425A1 (en) * 2017-04-03 2018-10-04 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIMITRIOS C. MASTELLOS等: "Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria", SEMIN HEMATOL., vol. 55, no. 3, pages 167 - 175, XP055711567, DOI: 10.1053/j.seminhematol.2018.02.002 *
汪道晨;车俊仪;徐明新;陈园园;陶颖;袁伟恩;: "普朗尼克F-127以及PLGA对多孔微球的影响", 现代生物医学进展, no. 34, pages 6626 - 6629 *

Also Published As

Publication number Publication date
TW202106290A (zh) 2021-02-16
KR20220004039A (ko) 2022-01-11
JP2022530042A (ja) 2022-06-27
EP3958842A1 (en) 2022-03-02
US20220211799A1 (en) 2022-07-07
IL287079A (en) 2021-12-01
SG11202109837SA (en) 2021-10-28
JP2025118607A (ja) 2025-08-13
AU2020261059A1 (en) 2021-10-14
MX2021013010A (es) 2022-01-18
JP7726791B2 (ja) 2025-08-20
CA3137895A1 (en) 2020-10-29
BR112021017820A2 (pt) 2022-02-08
WO2020219822A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
JP7379615B2 (ja) 補体活性のモジュレーター
JP7726791B2 (ja) 補体活性を調節するための組成物及び方法
JP2021505565A (ja) 補体活性のモジュレータ
US20220160820A1 (en) Modulators of complement activity
CN110087668A (zh) 补体活性的调节剂
HK40084222A (en) Modulators of complement activity
HK40031446B (en) Modulators of complement activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211126

WD01 Invention patent application deemed withdrawn after publication